1. Home
  2. CTY

as of 11-18-2026 10:44am EST

$17.55
+$0.00
+0.03%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

Founded: 2023 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 1.0B IPO Year: 2026
Target Price: $37.33 AVG Volume (30 days): 250.4K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $15.81 - $22.65 Next Earning Date: 12-01-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 62.96% Revenue Growth (next year): 7.47%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: